Matching articles for "breast cancer"
Issue 1759 · July 20, 2026
Vepdegestrant (Veppanu) for Advanced Breast Cancer

Vepdegestrant ( Veppanu – Rigel), an oral heterobifunctional protein degrader, has been approved by the FDA for treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2…

Med Lett Drugs Ther. 2026 Jul 20; 68(1759):e121-2 doi:10.58347/tml.2026.1759g
Vepdegestrant ( Veppanu – Rigel), an oral heterobifunctional protein degrader, has been approved by the FDA for treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer in adults who had disease progression following ≥1 prior line of endocrine therapy. It is the first proteolysis targeting chimera (PROTAC), a type of heterobifunctional protein degrader, to be approved in the US. The oral selective estrogen receptor degraders (SERDs) elacestrant (Orserdu) and imlunestrant (Inluriyo) were approved earlier for the same indication.
Issue 1755 · May 25, 2026 Free
In Brief: An Expanded Indication for Enhertu

Fam-trastuzumab deruxtecan ( Enhertu – Daiichi Sankyo/AstraZeneca) has now been approved by the FDA for use in combination with pertuzumab (Perjeta) for first-line treatment of HER2-positive unresectable or…

Med Lett Drugs Ther. 2026 May 25; 68(1755):87 doi:10.58347/tml.2026.1755d
Fam-trastuzumab deruxtecan ( Enhertu – Daiichi Sankyo/AstraZeneca) has now been approved by the FDA for use in combination with pertuzumab (Perjeta) for first-line treatment of HER2-positive unresectable or metastatic breast cancer. The drug was approved earlier for use as monotherapy in adults with previously treated HER2-positive unresectable or metastatic breast cancer.
Issue 1748 · February 16, 2026 Free
In Brief: Label Changes for Menopausal Hormone Therapy Products

The FDA has requested the removal of some boxed warnings from the labels of vaginal and systemic menopausal hormone therapy (MHT) products. The warnings were initially added in 2003 based on the results of two…

Med Lett Drugs Ther. 2026 Feb 16; 68(1748):30-1 doi:10.58347/tml.2026.1748d
The FDA has requested the removal of some boxed warnings from the labels of vaginal and systemic menopausal hormone therapy (MHT) products. The warnings were initially added in 2003 based on the results of two placebo-controlled Women's Health Initiative (WHI) trials evaluating the use of systemic hormones for primary prevention of coronary heart disease (CHD) in postmenopausal women 50-79 years old.
Issue 1746 · January 19, 2026
Imlunestrant (Inluriyo) for Advanced Breast Cancer

The FDA has approved imlunestrant ( Inluriyo – Lilly), an oral estrogen receptor antagonist, for treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative,…

Med Lett Drugs Ther. 2026 Jan 19; 68(1746):14-5 doi:10.58347/tml.2026.1746d
The FDA has approved imlunestrant ( Inluriyo – Lilly), an oral estrogen receptor antagonist, for treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer in adults who had disease progression following at least one prior line of endocrine therapy. Imlunestrant is the second oral selective estrogen receptor degrader (SERD) to be approved in the US for treatment of breast cancer; elacestrant (Orserdu) was approved in 2023.
Issue 1723 · March 3, 2025
Datopotamab Deruxtecan (Datroway) for Advanced Breast Cancer (online only)

The FDA has approved datopotamab deruxtecan ( Datroway – Daiichi Sankyo/AstraZeneca), a trophoblast cell-surface antigen-2 (Trop-2)-directed antibody and topoisomerase inhibitor conjugate, for treatment of…

Med Lett Drugs Ther. 2025 Mar 3; 67(1723):e41-2 doi:10.58347/tml.2025.1723e
The FDA has approved datopotamab deruxtecan ( Datroway – Daiichi Sankyo/AstraZeneca), a trophoblast cell-surface antigen-2 (Trop-2)-directed antibody and topoisomerase inhibitor conjugate, for treatment of adults with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer who received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
Issue 1717 · December 9, 2024
Ribociclib (Kisqali) for Early Breast Cancer (online only)

The oral cyclin-dependent kinase (CDK) 4/6 inhibitor ribociclib ( Kisqali – Novartis), which was approved by the FDA in 2017 for use with an aromatase inhibitor or fulvestrant for treatment of hormone…

Med Lett Drugs Ther. 2024 Dec 9; 66(1717):e202-3 doi:10.58347/tml.2024.1717f
The oral cyclin-dependent kinase (CDK) 4/6 inhibitor ribociclib ( Kisqali – Novartis), which was approved by the FDA in 2017 for use with an aromatase inhibitor or fulvestrant for treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, has now been approved for use with an aromatase inhibitor for adjuvant treatment of HR-positive, HER2-negative stage II or III early breast cancer at high risk of recurrence. Kisqali can be used in patients with node-positive or node-negative disease. The CDK 4/6 inhibitor abemaciclib (Verzenio) is also approved for use in early breast cancer, but only in patients with node-positive disease.
Issue 1696 · February 19, 2024
Capivasertib (Truqap) for Breast Cancer (online only)

The oral kinase inhibitor capivasertib ( Truqap – AstraZeneca), a first-in-class AKT inhibitor, has been approved by the FDA for use in combination with the selective estrogen receptor degrader (SERD)…

Med Lett Drugs Ther. 2024 Feb 19; 66(1696):e32-3 doi:10.58347/tml.2024.1696e
The oral kinase inhibitor capivasertib ( Truqap – AstraZeneca), a first-in-class AKT inhibitor, has been approved by the FDA for use in combination with the selective estrogen receptor degrader (SERD) fulvestrant ( Faslodex , and generics) for treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in adults with one or more PIK3CA/AKT1/PTEN-alterations who had disease progression on at least one endocrine-based regimen for metastatic disease or recurrence on or within 12 months of completing adjuvant therapy.
Issue 1674 · April 17, 2023 Free
In Brief: Olaparib (Lynparza) for High-Risk Early Breast Cancer (online only)

The oral poly(ADP-ribose) polymerase (PARP) inhibitor olaparib ( Lynparza – AstraZeneca) has been approved by the FDA for adjuvant treatment of adults with deleterious or suspected deleterious germline…

Med Lett Drugs Ther. 2023 Apr 17; 65(1674):e77-8 doi:10.58347/tml.2023.1674j
The oral poly(ADP-ribose) polymerase (PARP) inhibitor olaparib ( Lynparza – AstraZeneca) has been approved by the FDA for adjuvant treatment of adults with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative, high-risk early breast cancer who received prior neoadjuvant or adjuvant chemotherapy. The drug was previously approved for treatment of adults with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer who received chemotherapy in the neoadjuvant, adjuvant, or metastatic setting.
Issue 1673 · April 3, 2023 Free
In Brief: A New Indication for Abemaciclib (Verzenio) (online only)

The oral cyclin-dependent kinase (CDK) 4/6 inhibitor abemaciclib (Verzenio – Lilly) has been approved by the FDA for use in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for…

Med Lett Drugs Ther. 2023 Apr 3; 65(1673):e62-3 doi:10.58347/tml.2023.1673g
The oral cyclin-dependent kinase (CDK) 4/6 inhibitor abemaciclib (Verzenio – Lilly) has been approved by the FDA for use in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence.1It was previously approved for the same indication, but patients were also required to have a Ki-67 score ≥20%. About 70% of all breast cancers are HR-positive and HER2-negative. Ki-67 is a prognostic biomarker for tumor proliferation; a score ≥20% is associated with early recurrence and poor prognosis.
Issue 1673 · April 3, 2023 Free
In Brief: Fam-trastuzumab deruxtecan (Enhertu) for Breast Cancer (online only)

Fam-trastuzumab deruxtecan-nxki ( Enhertu – Daiichi Sankyo/AstraZeneca), which received accelerated approval by the FDA in 2019 for treatment of HER2-positive breast cancer based on its rate and duration of…

Med Lett Drugs Ther. 2023 Apr 3; 65(1673):e60-1 doi:10.58347/tml.2023.1673f
Fam-trastuzumab deruxtecan-nxki ( Enhertu – Daiichi Sankyo/AstraZeneca), which received accelerated approval by the FDA in 2019 for treatment of HER2-positive breast cancer based on its rate and duration of response,1 has been granted regular approval for treatment of adults with unresectable or metastatic HER2-positive breast cancer who received a prior anti-HER2-based regimen in the metastatic setting or in the neoadjuvant or adjuvant setting and developed recurrence during or within 6 months of completing treatment.
Issue 1671 · March 6, 2023
Elacestrant (Orserdu) for Advanced or Metastatic Breast Cancer

The FDA has approved elacestrant ( Orserdu – Stemline), an oral estrogen receptor antagonist, for treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative,…

Med Lett Drugs Ther. 2023 Mar 6; 65(1671):38-40 doi:10.58347/tml.2023.1671d
The FDA has approved elacestrant ( Orserdu – Stemline), an oral estrogen receptor antagonist, for treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer in postmenopausal women or men who had disease progression following endocrine therapy. Elacestrant is the first oral selective estrogen receptor degrader (SERD) to be approved for treatment of breast cancer; the injectable SERD fulvestrant ( Faslodex , and generics) was approved more than 20 years ago.
Issue 1671 · March 6, 2023 Free
In Brief: A New Breast Cancer Indication for Sacituzumab Govitecan (Trodelvy) (online only)

Sacituzumab govitecan-hziy ( Trodelvy – Gilead) has been approved for treatment of unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2…

Med Lett Drugs Ther. 2023 Mar 6; 65(1671):e43-4 doi:10.58347/tml.2023.1671g
Sacituzumab govitecan-hziy ( Trodelvy – Gilead) has been approved for treatment of unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer in adults who received prior endocrine therapy and ≥2 additional systemic therapies for metastatic disease. It was previously approved for treatment-refractory metastatic triplenegative breast cancer and for treatment of locally advanced or metastatic urothelial cancer in adults who received platinum-based chemotherapy and a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.
Issue 1664 · November 28, 2022
Margetuximab (Margenza) for HER2-Positive Breast Cancer (online only)

The FDA has approved margetuximab-cmkb ( Margenza – MacroGenics), a HER2/neu receptor antagonist, for use in combination with chemotherapy for treatment of metastatic human epidermal growth factor receptor 2…

Med Lett Drugs Ther. 2022 Nov 28; 64(1664):e195-6
The FDA has approved margetuximab-cmkb ( Margenza – MacroGenics), a HER2/neu receptor antagonist, for use in combination with chemotherapy for treatment of metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer in adults who received ≥2 prior anti-HER2 regimens, at least one of which was for metastatic disease.
Issue 1663 · November 14, 2022
Neratinib (Nerlynx) for Metastatic HER2-Positive Breast Cancer (online only)

The oral tyrosine kinase inhibitor neratinib ( Nerlynx – Puma Biotechnology) has been approved by the FDA for use in combination with capecitabine ( Xeloda , and generics) for treatment of advanced or…

Med Lett Drugs Ther. 2022 Nov 14; 64(1663):e192-3
The oral tyrosine kinase inhibitor neratinib ( Nerlynx – Puma Biotechnology) has been approved by the FDA for use in combination with capecitabine ( Xeloda , and generics) for treatment of advanced or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer in adults who received ≥2 prior anti-HER2-based regimens for metastatic disease. It was previously approved for use as monotherapy for extended adjuvant treatment of adults with early-stage, HER2-positive breast cancer following adjuvant trastuzumab (Herceptin) -based therapy. HER2 is overexpressed in about 20% of breast cancers. Up to 30% of early-stage, HER2-positive breast cancer cases treated with trastuzumab-based adjuvant therapy recur. Neratinib is the only HER2-directed small molecule approved for treatment of early-stage and metastatic HER2-postive breast cancer.
Issue 1639 · December 13, 2021 Free
In Brief: Abemaciclib (Verzenio) for Early Breast Cancer

The oral cyclin-dependent kinase (CDK) 4/6 inhibitor abemaciclib ( Verzenio – Lilly), which was approved by the FDA in 2017 for treatment of hormone receptor (HR)-positive, human epidermal growth factor…

Med Lett Drugs Ther. 2021 Dec 13; 63(1639):199-200
The oral cyclin-dependent kinase (CDK) 4/6 inhibitor abemaciclib ( Verzenio – Lilly), which was approved by the FDA in 2017 for treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, has now been approved for use in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for adjuvant treatment of patients with HR-positive, HER2-negative, node-positive, early breast cancer at high risk of recurrence and a Ki-67 score ≥20%.
Issue 1619 · March 16, 2021
In Brief: Phesgo - A Fixed-Dose Combination for HER-2 Positive Breast Cancer (online only)

The FDA has approved a fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase ( Phesgo – Genentech) for use in combination with chemotherapy for neoadjuvant (preoperative) treatment of human…

Med Lett Drugs Ther. 2021 Mar 16; 63(1619):e1-2
The FDA has approved a fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase ( Phesgo – Genentech) for use in combination with chemotherapy for neoadjuvant (preoperative) treatment of human epidermal growth factor receptor 2 (HER2)-positive, locally advanced, inflammatory, or early-stage breast cancer, or for adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence, or with docetaxel for treatment of those with HER2-positive metastatic breast cancer who have not received anti-HER2 therapy or chemotherapy for metastatic disease. Phesgo is the first combination that contains pertuzumab and trastuzumab for SC administration. IV pertuzumab (Perjeta) and IV and SC trastuzumab ( Herceptin , and others) have been available for years for treatment of HER-2 positive breast cancer.
Issue 1617 · February 8, 2021
Sacituzumab Govitecan (Trodelvy) for Metastatic Triple-Negative Breast Cancer (online only)

The FDA has approved sacituzumab govitecan-hziy ( Trodelvy – Immunomedics), a trophoblast cell-surface antigen-2 (Trop-2)-directed antibody and topoisomerase inhibitor conjugate, for treatment of adults with…

Med Lett Drugs Ther. 2021 Feb 8; 63(1617):e24-5
The FDA has approved sacituzumab govitecan-hziy ( Trodelvy – Immunomedics), a trophoblast cell-surface antigen-2 (Trop-2)-directed antibody and topoisomerase inhibitor conjugate, for treatment of adults with metastatic triple-negative breast cancer who have received ≥2 prior therapies for metastatic disease. It is the first Trop-2-directed antibody-drug conjugate to become available in the US.
Issue 1611 · November 16, 2020
Two Drugs for Advanced HER2-Positive Breast Cancer (Enhertu and Tukysa)

The FDA has approved two new drugs for treatment of previously-treated unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer: fam-trastuzumab deruxtecannxki (…

Med Lett Drugs Ther. 2020 Nov 16; 62(1611):182-4
The FDA has approved two new drugs for treatment of previously-treated unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer: fam-trastuzumab deruxtecannxki ( Enhertu – Daiichi-Sankyo/AstraZeneca), an IV HER2-directed monoclonal antibody linked to the topoisomerase I inhibitor DXd, and tucatinib ( Tukysa – Seagen), an oral tyrosine kinase inhibitor.
Issue 1566 · February 25, 2019
Oxybutynin for Hot Flashes in Women with Breast Cancer

Interim results of a double-blind, placebo-controlled trial suggest that off-label use of the anticholinergic drug oxybutynin may reduce the frequency and severity of hot flashes in women with breast cancer.…

Med Lett Drugs Ther. 2019 Feb 25; 61(1566):30-1
Interim results of a double-blind, placebo-controlled trial suggest that off-label use of the anticholinergic drug oxybutynin may reduce the frequency and severity of hot flashes in women with breast cancer. Extended-release oral oxybutynin ( Ditropan XL , and generics) has been shown to reduce the frequency and severity of hot flashes in healthy menopausal women.
Issue 1557 · October 8, 2018
Choice of Contraceptives

Intrauterine devices (IUDs) and the etonogestrel implant are the most effective reversible contraceptive methods available. Hormonal oral contraceptives, patches, rings, and injectables are also highly…

Med Lett Drugs Ther. 2018 Oct 8; 60(1557):161-8
Intrauterine devices (IUDs) and the etonogestrel implant are the most effective reversible contraceptive methods available. Hormonal oral contraceptives, patches, rings, and injectables are also highly effective in preventing pregnancy. When used alone, barrier and fertility-based methods generally have higher failure rates than other methods.
Issue 1539 · January 29, 2018
Neratinib (Nerlynx) for HER2-Positive Breast Cancer

The FDA has approved the oral tyrosine kinase inhibitor neratinib ( Nerlynx – Puma Biotechnology) for extended adjuvant treatment of adults with early-stage, human epidermal growth factor receptor 2…

Med Lett Drugs Ther. 2018 Jan 29; 60(1539):23
The FDA has approved the oral tyrosine kinase inhibitor neratinib ( Nerlynx – Puma Biotechnology) for extended adjuvant treatment of adults with early-stage, human epidermal growth factor receptor 2 (HER2)-positive breast cancer, following adjuvant trastuzumab ( Herceptin )-based therapy. HER2 is overexpressed in about 20% of breast cancers. Up to 30% of early-stage, HER2-positive breast cancer cases treated with trastuzumab-based adjuvant therapy recur.
Issue 1533 · November 6, 2017
Abemaciclib (Verzenio) - A Third CDK 4/6 Inhibitor for Breast Cancer

The FDA has approved abemaciclib ( Verzenio – Lilly), an oral cyclin-dependent kinase (CDK) 4/6 inhibitor, for treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2…

Med Lett Drugs Ther. 2017 Nov 6; 59(1533):185-6
The FDA has approved abemaciclib ( Verzenio – Lilly), an oral cyclin-dependent kinase (CDK) 4/6 inhibitor, for treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. Abemaciclib is the third CDK 4/6 inhibitor to be approved in the US for this indication.
Issue 1532 · October 23, 2017
Ribociclib (Kisqali) for Advanced or Metastatic Breast Cancer (online only)

The oral cyclin-dependent kinase (CDK) 4/6 inhibitor ribociclib ( Kisqali – Novartis) has been approved by the FDA for use in combination with an aromatase inhibitor for first-line endocrine-based therapy in…

Med Lett Drugs Ther. 2017 Oct 23; 59(1532):e178-9
The oral cyclin-dependent kinase (CDK) 4/6 inhibitor ribociclib ( Kisqali – Novartis) has been approved by the FDA for use in combination with an aromatase inhibitor for first-line endocrine-based therapy in postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. Ribociclib is also available copackaged with the aromatase inhibitor letrozole ( Femara , and generics) as Kisqali Femara Co-Pack . Ribociclib is the second CDK 4/6 inhibitor to be approved in the US for this indication; palbociclib (Ibrance) was the first. Abemaciclib (Verzenio) , a third CDK 4/6 inhibitor, was recently approved and will be reviewed in a future issue.
Issue 1498 · July 4, 2016 Free
In Brief: Uridine Triacetate (Vistogard) for Fluorouracil Overdose

The FDA has approved the pyrimidine analog uridine triacetate ( Vistogard – Wellstat Therapeutics) for emergency treatment of a fluorouracil (5-FU) or capecitabine ( Xeloda , and generics) overdose or severe…

Med Lett Drugs Ther. 2016 Jul 4; 58(1498):90
The FDA has approved the pyrimidine analog uridine triacetate ( Vistogard – Wellstat Therapeutics) for emergency treatment of a fluorouracil (5-FU) or capecitabine ( Xeloda , and generics) overdose or severe toxicity that occurs within 96 hours following administration of one of these drugs. Fluorouracil is a cytotoxic antimetabolite used to treat breast, colorectal, and other cancers; capecitabine is an oral prodrug of fluorouracil. Uridine triacetate, a prodrug, is deacetylated to uridine after oral administration. Excess circulating uridine is converted into uridine triphosphate, which inhibits the cytotoxic activity of 5-fluorouridine triphosphate, a fluorouracil metabolite, by competing with it for incorporation into RNA. FDA approval was based on two unpublished open-label studies (summarized in the package insert) in a total of 135 adults and children with overdoses of fluorouracil or capecitabine (n=117) or severe or life-threatening toxicities within 96 hours after their administration (n=18). The overall survival rate at 30 days was 96%. In retrospective case reports that included 25 patients who received only supportive care after a fluorouracil overdose, the survival rate was 16%. Vistogard is supplied as orange-flavored oral granules in single-dose packets containing 10 grams of uridine triacetate. The granules should be mixed with 3-4 ounces of soft food and taken every 6 hours for 20 doses. The recommended dose is 10 grams for adults and 6.2 grams/m 2 (10 grams maximum) for children. Mild to moderate nausea, vomiting, and diarrhea have been reported. The cost for one course of treatment is $75,000. 1 Approximate WAC. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. June 5, 2016. Reprinted with permission by First Databank, Inc. All rights reserved. ©2016. www.fdbhealth.com/policies/drug-pricing-policy. Download complete U.S. English article
Issue 1495 · May 23, 2016
Antimicrobial Prophylaxis for Surgery

Antimicrobial prophylaxis can decrease the incidence of postoperative surgical site infection after some procedures. Since the last Medical Letter article on this subject, consensus guidelines have been…

Med Lett Drugs Ther. 2016 May 23; 58(1495):63-8
Antimicrobial prophylaxis can decrease the incidence of postoperative surgical site infection after some procedures. Since the last Medical Letter article on this subject, consensus guidelines have been published. Recommendations for prophylaxis in specific surgical procedures are listed in Table 1.
Issue 1494 · May 9, 2016 Free
In Brief: Two Drugs for Soft-Tissue Sarcoma (online only)

The anthracycline doxorubicin with or without the alkylating agent ifosfamide is the standard first-line treatment for advanced soft-tissue sarcomas. The FDA recently approved the minor groove DNA intercalator…

Med Lett Drugs Ther. 2016 May 9; 58(1494):e62
The anthracycline doxorubicin with or without the alkylating agent ifosfamide is the standard first-line treatment for advanced soft-tissue sarcomas. The FDA recently approved the minor groove DNA intercalator trabectedin ( Yondelis – Janssen) for treatment of unresectable or metastatic liposarcoma or leiomyosarcoma in patients previously treated with an anthracycline. Trabectedin has been available for years in Europe for treatment of advanced soft-tissue sarcoma. The FDA has also approved the microtubule inhibitor eribulin mesylate ( Halaven – Eisai), which was approved earlier for treatment of metastatic breast cancer, 1 for treatment of unresectable or metastatic liposarcoma, but not for leiomyosarcoma, in patients previously treated with an anthracycline. Trabectedin binds guanine residues in the minor groove of DNA, which inhibits active transcription and blocks DNA repair proteins to achieve an antiproliferative effect. 2 It has not been shown to be superior to doxorubicin for first-line treatment of advanced soft-tissue sarcomas, 3 but has shown activity in anthracycline- and alkylating agent-resistant soft tissue sarcomas. 4 FDA approval of trabectedin was based on a randomized, open-label trial comparing it to dacarbazine in 518 heavily pretreated patients with metastatic or recurrent leiomyosarcoma or liposarcoma. Median progression-free survival was significantly longer with trabectedin (4.2 months vs 1.5 months with dacarbazine). Median overall survival, however, was not significantly different (12.4 months with trabectedin vs 12.9 months with dacarbazine). 5 Adverse effects of trabectedin include nausea, fatigue, neutropenia, and transient hepatic enzyme elevations. 6 Trabectedin is administered over 24 hours through a central venous line every 3 weeks until disease progression or unacceptable toxicity occurs. Eribulin mesylate is a microtubule-polymerizing drug that sequesters tubulin into nonfunctional aggregates. 7 FDA approval of eribulin for treatment of advanced liposarcoma was based on a randomized, open-label trial comparing it to dacarbazine in 452 patients with unresectable or metastatic liposarcoma or leiomyosarcoma previously treated with an anthracycline. Median progression-free survival was 2.6 months in both groups, but overall survival was significantly longer with eribulin (13.5 months vs 11.5 months with dacarbazine). A pre-planned subgroup analysis found that the benefit was limited to patients with liposarcoma. 8 Eribulin is the first drug shown to prolong overall survival in patients with advanced liposarcoma. The incidence of grade 3 or 4 adverse effects, particularly leukopenia and neutropenia, was higher with eribulin (67%) than with dacarbazine (56%). Fatigue, alopecia, peripheral neuropathy, nausea, and constipation also occurred. Eribulin is administered IV over 2 to 5 minutes on days 1 and 8 of a 3-week cycle. Eribulin mesylate (Halaven) for breast cancer. Med Lett Drugs Ther 2011; 53:30. AK Larsen et al. Unique features of trabectedin mechanism of action. Cancer Chemother Pharmacol 2015; 77:663. B Bui-Nguyen et al. A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: the TRUSTS trial. Eur J Cancer 2015; 51:1312. BJ Petek et al. Trabectedin in soft tissue sarcomas. Mar Drugs 2015; 13:974. GD Demetri et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol 2016; 34:786. C Leporini et al. A comprehensive safety evaluation of trabectedin and drug-drug interactions of trabectedin-based combinations. BioDrugs 2014; 28:499. NF Dybdal-Hargreaves et al. Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent. Clin Cancer Res 2015; 21:2445. P Schöffski et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet 2016 February 10 (epub). Download complete U.S. English article
Issue 1490 · March 14, 2016
Zarxio - A Filgrastim Biosimilar

The FDA has approved filgrastim-sndz ( Zarxio – Sandoz), a biosimilar of the recombinant human granulocyte colony-stimulating factor filgrastim (G-CSF; Neupogen ), which has been available in the US since…

Med Lett Drugs Ther. 2016 Mar 14; 58(1490):34-5
The FDA has approved filgrastim-sndz ( Zarxio – Sandoz), a biosimilar of the recombinant human granulocyte colony-stimulating factor filgrastim (G-CSF; Neupogen ), which has been available in the US since 1991. Zarxio is the first biosimilar product to be approved in the US; it has been available in Europe as Zarzio since 2009.
Issue 1475 · August 17, 2015
Palbociclib (Ibrance) for Metastatic Breast Cancer

Palbociclib ( Ibrance – Pfizer), an oral cyclin-dependent kinase inhibitor, has been approved by the FDA for use in combination with the aromatase inhibitor letrozole ( Femara , and generics) for first-line…

Med Lett Drugs Ther. 2015 Aug 17; 57(1475):115-6
Palbociclib ( Ibrance – Pfizer), an oral cyclin-dependent kinase inhibitor, has been approved by the FDA for use in combination with the aromatase inhibitor letrozole ( Femara , and generics) for first-line treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. It is the first cyclin-dependent kinase inhibitor to become available in the US.
Issue 1431 · December 9, 2013
Pertuzumab (Perjeta) for Preoperative Use in HER2-Positive Breast Cancer

The FDA has approved the neoadjuvant (preoperative) use of pertuzumab ( Perjeta – Genentech) in combination with trastuzumab (Herceptin) and docetaxel ( Taxotere , and generics) for treatment of locally…

Med Lett Drugs Ther. 2013 Dec 9; 55(1431):98-9
The FDA has approved the neoadjuvant (preoperative) use of pertuzumab ( Perjeta – Genentech) in combination with trastuzumab (Herceptin) and docetaxel ( Taxotere , and generics) for treatment of locally advanced, inflammatory, or early-stage HER2 (human epidermal growth factor receptor 2)-positive breast cancer patients with tumors >2 cm in diameter or node-positive disease. Pertuzumab in combination with trastuzumab and docetaxel was approved earlier for treatment of HER2-positive metastatic breast cancer. Pertuzumab is the first drug to be approved for neoadjuvant treatment of breast cancer.
Issue 1428 · October 28, 2013
Paroxetine (Brisdelle) for Hot Flashes

The FDA has approved a low-dose formulation of the selective serotonin reuptake inhibitor (SSRI) paroxetine mesylate ( Brisdelle – Noven Therapeutics) for treatment of moderate-to-severe vasomotor symptoms…

Med Lett Drugs Ther. 2013 Oct 28; 55(1428):85-6
The FDA has approved a low-dose formulation of the selective serotonin reuptake inhibitor (SSRI) paroxetine mesylate ( Brisdelle – Noven Therapeutics) for treatment of moderate-to-severe vasomotor symptoms associated with menopause. It is the first non-hormonal therapy to be approved for this indication. Paroxetine mesylate (Pexeva) and paroxetine hydrochloride ( Paxil , and generics) are marketed in higher doses for treatment of depression and other psychiatric disorders.
Issue 1425 · September 16, 2013
Ado-Trastuzumab Emtansine (Kadcyla) for HER2-Positive Metastatic Breast Cancer

Ado-trastuzumab emtansine ( Kadcyla – Genentech), a human epidermal growth factor receptor 2 (HER2)-targeted antibody and microtubule inhibitor conjugate, has been approved by the FDA for intravenous (IV)…

Med Lett Drugs Ther. 2013 Sep 16; 55(1425):75-6
Ado-trastuzumab emtansine ( Kadcyla – Genentech), a human epidermal growth factor receptor 2 (HER2)-targeted antibody and microtubule inhibitor conjugate, has been approved by the FDA for intravenous (IV) treatment of HER2-positive metastatic breast cancer in patients previously treated with trastuzumab (Herceptin) and a taxane. The prefix was added to the new conjugate’s name at the request of the FDA to distinguish it from trastuzumab.
Issue 124 · December 1, 2012
Cancer Screening

Use of screening tests to identify cancers before they cause symptoms can lead to earlier therapy and may improve outcomes. Screening tests for some common cancers are reviewed below.

Treat Guidel Med Lett. 2012 Dec; 10(124):87-94
Use of screening tests to identify cancers before they cause symptoms can lead to earlier therapy and may improve outcomes. Screening tests for some common cancers are reviewed below.
Issue 1395 · July 23, 2012
Pertuzumab (Perjeta) for HER2-Positive Metastatic Breast Cancer

Pertuzumab ( Perjeta – Roche/Genentech), a humanized monoclonal antibody, has been approved by the FDA for use in combination with trastuzumab (Herceptin) and docetaxel ( Taxotere , and others) for…

Med Lett Drugs Ther. 2012 Jul 23; 54(1395):59-60
Pertuzumab ( Perjeta – Roche/Genentech), a humanized monoclonal antibody, has been approved by the FDA for use in combination with trastuzumab (Herceptin) and docetaxel ( Taxotere , and others) for first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer.
Issue 1382 · January 23, 2012
Beta-Adrenergic Blockers and Breast Cancer

Three retrospective studies have recently reported an association between beta-blocker use and a reduction in breast cancer metastasis and recurrence. No prospective, randomized trials have been published.

Med Lett Drugs Ther. 2012 Jan 23; 54(1382):6-7
Three retrospective studies have recently reported an association between beta-blocker use and a reduction in breast cancer metastasis and recurrence. No prospective, randomized trials have been published.
Issue 1366 · June 13, 2011
Aromatase Inhibitors for Adjuvant Treatment of Postmenopausal Breast Cancer

Adjuvant hormone therapy with anti-estrogen drugs has been shown to reduce disease recurrence and mortality in postmenopausal women with estrogen receptor (ER)-positive breast cancer. In recent years,…

Med Lett Drugs Ther. 2011 Jun 13; 53(1366):47-8
Adjuvant hormone therapy with anti-estrogen drugs has been shown to reduce disease recurrence and mortality in postmenopausal women with estrogen receptor (ER)-positive breast cancer. In recent years, aromatase inhibitors (AI) have become the preferred first-line hormonal treatment over tamoxifen for such patients.1,2
Issue 1366 · June 13, 2011 Free
In Brief: An Aromatase Inhibitor Is Reported to Prevent Postmenopausal Breast Cancer

A randomized, placebo-controlled, double-blind trial of exemestane ( Aromasin , and others) in postmenopausal women considered at increased risk for breast cancer found that the aromatase inhibitor, over a…

Med Lett Drugs Ther. 2011 Jun 13; 53(1366):48
A randomized, placebo-controlled, double-blind trial of exemestane ( Aromasin , and others) in postmenopausal women considered at increased risk for breast cancer found that the aromatase inhibitor, over a median follow-up of 35 months, significantly decreased the annual incidence of invasive breast cancer from 0.55% to 0.19% (PE Goss et al. N Engl J Med, epub June 4, 2011).
Issue 1362 · April 18, 2011
Eribulin Mesylate (Halaven) for Breast Cancer

Eribulin mesylate ( Halaven – Eisai) has been approved by the FDA for treatment of patients with metastatic breast cancer who have previously received at least 2 chemotherapy regimens for metastatic cancer.…

Med Lett Drugs Ther. 2011 Apr 18; 53(1362):30-1
Eribulin mesylate ( Halaven – Eisai) has been approved by the FDA for treatment of patients with metastatic breast cancer who have previously received at least 2 chemotherapy regimens for metastatic cancer. Prior therapy should have included an anthracycline and a taxane in either an adjuvant or metastatic setting. Other drugs used to treat anthracycline- and taxane-refractory metastatic breast cancer include capecitabine (Xeloda) , gemcitabine ( Gemzar , and others) and vinorelbine ( Navelbine , and others).
Issue 1327 · December 14, 2009 Free
Screening Mammography for Women 40-49 Years Old

Conflicting recommendations on when to screen for breast cancer are problematic for healthcare providers. The recent recommendation by the US Preventive Services Task Force (USPSTF) against routine screening…

Med Lett Drugs Ther. 2009 Dec 14; 51(1327):97-8
Conflicting recommendations on when to screen for breast cancer are problematic for healthcare providers. The recent recommendation by the US Preventive Services Task Force (USPSTF) against routine screening mammography for women 40-49 years old conflicts with recommendations made by other organizations such as the American Cancer Society and earlier recommendations made by the USPSTF in 2002. Click here to view the free full article.
Issue 1314 · June 15, 2009 Free
In Brief: Tamoxifen and SSRI Interactions

Use of a selective serotonin reuptake inhibitor (SSRI) is common in women taking tamoxifen ( Nolvadex , and others) for breast cancer, both to treat depression and to decrease hot flashes. However, tamoxifen…

Med Lett Drugs Ther. 2009 Jun 15; 51(1314):45-6
Use of a selective serotonin reuptake inhibitor (SSRI) is common in women taking tamoxifen ( Nolvadex , and others) for breast cancer, both to treat depression and to decrease hot flashes. However, tamoxifen must be metabolized by CYP2D6 to become pharmacologically fully active (MJ Higgins et al. J Natl Compr Canc Netw 2009; 7:203) , and the SSRIs fluoxetine ( Prozac , and others) and paroxetine ( Paxil , and others) are strong inhibitors of CYP2D6. Sertraline ( Zoloft , and others) inhibits CYP2D6 to a lesser extent. Citalopram ( Celexa , and others) and escitalopram (Lexapro) , the 2 other SSRIs approved for treatment of depression, are only weak inhibitors of CYP2D6. Two observational studies presented at a recent meeting of the American Society of Clinical Oncology (45th annual meeting, May 29-June 2, 2009, Orlando, FL abstracts CRA508, CRA509) examined the effect of strong inhibitors of CYP2D6 on the success rate of tamoxifen in preventing recurrence of breast cancer. One found that women who took fluoxetine, paroxetine or sertraline (or bupropion, duloxetine, terbinafine, quinidine or long-term diphenhydramine) with tamoxifen had a higher 2-year recurrence rate (13.9% vs. 7.5%). The other study found no association between cancer recurrence and use of a CYP2D6 inhibitor. There is no good evidence that any one SSRI is more effective than any other for treatment of depression. For women who are taking tamoxifen and need to begin treatment with an SSRI to treat depression, citalopram or escitalopram might be the safest choice (Treat Guidel Med Lett 2006; 4:35) . Use of an SSRI to treat hot flashes in women taking tamoxifen should probably be reconsidered. Download: U.S. English
Issue 74 · October 1, 2008
Drugs for Postmenopausal Osteoporosis

Osteoporosis is characterized by low bone mass with microarchitectural disruption and skeletal fragility that results in an increased risk of fracture. The diagnosis has traditionally been established by bone…

Treat Guidel Med Lett. 2008 Oct; 6(74):67-74
Osteoporosis is characterized by low bone mass with microarchitectural disruption and skeletal fragility that results in an increased risk of fracture. The diagnosis has traditionally been established by bone densitometry, which is generally reported in terms of standard deviations (SD) from mean values in young adults (T score). The World Health Organization (WHO) has defined normal bone mineral density (BMD) for women as a value within one SD of the young adult mean. Values 2.5 SD (T score -2.5) or more below the mean are defined as osteoporosis. The WHO has developed a computerized model (FRAX) that predicts the 10-year probability of hip fracture based on clinical risk factors and BMD at the femoral neck.
Issue 1287 · June 2, 2008
Bevacizumab (Avastin) for Metastatic Breast Cancer

Bevacizumab ( Avastin - Genentech) is a recombinant humanized monoclonal antibody that binds to vascular endothelial growth factor and prevents it from binding to receptors on endothelial cells, inhibiting…

Med Lett Drugs Ther. 2008 Jun 2; 50(1287):42-3
Bevacizumab ( Avastin - Genentech) is a recombinant humanized monoclonal antibody that binds to vascular endothelial growth factor and prevents it from binding to receptors on endothelial cells, inhibiting formation of new blood vessels. Previously approved by the FDA for use in combination regimens for first-line treatment of metastatic colon cancer and metastatic non-small cell lung cancer, and used off-label for treatment of agerelated macular degeneration, it has now also been approved by the FDA for use in combination with paclitaxel ( Taxol , and others) for first-line treatment of HER2-negative metastatic breast cancer.
Issue 1278 · January 28, 2008
Ixabepilone (Ixempra) for Breast Cancer

Ixabepilone (ix ab ep' i lone; Ixempra - Bristol-Myers Squibb), a semisynthetic epothilone analog, has been approved by the FDA for treatment of advanced breast cancer. It is indicated for use in combination…

Med Lett Drugs Ther. 2008 Jan 28; 50(1278):7-8
Ixabepilone (ix ab ep' i lone; Ixempra - Bristol-Myers Squibb), a semisynthetic epothilone analog, has been approved by the FDA for treatment of advanced breast cancer. It is indicated for use in combination with capecitabine ( Xeloda - Roche) for treatment of locally advanced or metastatic breast cancer after failure of an anthracycline such as doxorubicin ( Adriamycin ) and a taxane such as paclitaxel ( Taxol , and others). It is also approved as monotherapy for treatment of metastatic or locally advanced breast cancer after an anthracycline, a taxane and capecitabine have failed.
Issue 1274 · November 19, 2007 Free
BRCA Screening

Direct-to-consumer advertisements are urging women to be tested for mutations in BRCA1 and BRCA2 genes, which are the most common known causes of an inherited predisposition to breast and ovarian cancer.…

Med Lett Drugs Ther. 2007 Nov 19; 49(1274):93-4
Direct-to-consumer advertisements are urging women to be tested for mutations in BRCA1 and BRCA2 genes, which are the most common known causes of an inherited predisposition to breast and ovarian cancer. Clinically important BRCA mutations have been found in about 2% of Ashkenazi Jewish women, and are estimated to occur in about 1 in 300 to 500 women in the general non-Jewish US population. The prevalence appears to be lower in non-whites.
Issue 1269 · September 10, 2007
Lapatinib (Tykerb) for Advanced Breast Cancer

Lapatinib ( Tykerb - GlaxoSmithKline), an oral inhibitor of both HER-2 and epidermal growth factor receptor type 1 (EGFR-1 or ErbB-1), has been approved by the FDA for use in combination with capecitabine…

Med Lett Drugs Ther. 2007 Sep 10; 49(1269):74-5
Lapatinib ( Tykerb - GlaxoSmithKline), an oral inhibitor of both HER-2 and epidermal growth factor receptor type 1 (EGFR-1 or ErbB-1), has been approved by the FDA for use in combination with capecitabine (Xeloda) to treat advanced or metastatic breast cancer that overexpresses HER-2 in patients who have received prior therapy that included an anthracycline, a taxane and trastuzumab (Herceptin) , an intravenous monoclonal antibody that also inhibits HER-2.
Issue 1234 · May 8, 2006
Raloxifene (Evista) for Breast Cancer Prevention in Postmenopausal Women

Preliminary results from a new study, unpublished but reported in a press release from the National Cancer Institute and widely disseminated in the public press, suggest that raloxifene (Evista) might be a…

Med Lett Drugs Ther. 2006 May 8; 48(1234):37
Preliminary results from a new study, unpublished but reported in a press release from the National Cancer Institute and widely disseminated in the public press, suggest that raloxifene (Evista) might be a better choice than tamoxifen ( Nolvadex , and others) for prevention of breast cancer in high-risk postmenopausal women.
Issue 1208 · May 9, 2005
Albumin-Bound Paclitaxel (Abraxane) for Advanced Breast Cancer

A new albumin-bound formulation of paclitaxel ( Abraxane - American Pharmaceutical Partners) has been approved by the FDA for treatment of metastatic breast cancer after failure of combination chemotherapy or…

Med Lett Drugs Ther. 2005 May 9; 47(1208):39-40
A new albumin-bound formulation of paclitaxel ( Abraxane - American Pharmaceutical Partners) has been approved by the FDA for treatment of metastatic breast cancer after failure of combination chemotherapy or relapse within 6 months of adjuvant chemotherapy. This formulation is free of polyoxyethylated castor oil (Cremophor), a solvent thought to contribute to the hypersensitivity reactions that occur frequently with standard paclitaxel (Taxol, and others) and are severe in about 3% of patients.
Issue 29 · January 1, 2005
Drugs for Breast Cancer

In addition to surgery and radiation therapy, a variety of drugs are used both singly and in combination to treat breast cancer. This article summarizes the principles of adjuvant therapy and treatment for…

Treat Guidel Med Lett. 2005 Jan; 3(29):1-6
In addition to surgery and radiation therapy, a variety of drugs are used both singly and in combination to treat breast cancer. This article summarizes the principles of adjuvant therapy and treatment for metastatic disease. A summary of individual drugs and their adverse effects begins on page 3.
Issue 1152 · March 17, 2003
Anastrozole (Arimidex) vs. Tamoxifen for Treatment of Early Breast Cancer

Anastrozole ( Arimidex - AstraZeneca, Medical Letter 1996; 38:61), an aromatase inhibitor, has received accelerated approval from the FDA for adjuvant treatment of postmenopausal women with early…

Med Lett Drugs Ther. 2003 Mar 17; 45(1152):22-3
Anastrozole ( Arimidex - AstraZeneca, Medical Letter 1996; 38:61), an aromatase inhibitor, has received accelerated approval from the FDA for adjuvant treatment of postmenopausal women with early hormone-receptor-positive breast cancer. The drug was approved for treatment of postmenopausal women with metastatic breast cancer in 1996.
Issue 7 · March 1, 2003
Drugs of Choice for Cancer

The tables in this article list drugs used for treatment of cancer in the USA and Canada and their major adverse effects. The choice of drugs in Table I is based on the opinions of Medical Letter consultants.…

Treat Guidel Med Lett. 2003 Mar; 1(7):41-52
The tables in this article list drugs used for treatment of cancer in the USA and Canada and their major adverse effects. The choice of drugs in Table I is based on the opinions of Medical Letter consultants. Some drugs are listed for indications for which they have not been approved by the US Food and Drug Administration. In some cases, such as elderly patients or those with many co-morbid illnesses, the regimen of choice might not be suitable. For many of the cancers listed, surgery and/or radiation therapy may be the treatment of choice or may also be part of the management. Anticancer drugs and their adverse effects are listed in Table II on page 46. A partial list of brand names appears on page 52.
Issue 1135 · July 22, 2002
Fulvestrant (Faslodex) for Advanced Breast Cancer

Fulvestrant ( Faslodex -- AstraZeneca), an estrogen receptor antagonist given intramuscularly (IM) once a month, was recently approved by the FDA for treatment of hormone-receptor-positive metastatic breast…

Med Lett Drugs Ther. 2002 Jul 22; 44(1135):65-6
Fulvestrant ( Faslodex -- AstraZeneca), an estrogen receptor antagonist given intramuscularly (IM) once a month, was recently approved by the FDA for treatment of hormone-receptor-positive metastatic breast cancer in postmenopausal women with disease progession on tamoxifen ( Nolvadex , and others) or another antiestrogen.
Issue 984 · September 27, 1996
Docetaxel (Taxotere) for Advanced Breast Cancer

Docetaxel ( Taxotere - Rh ne-Poulenc Rorer), a semisynthetic taxoid similar to paclitaxel ( Taxol - Medical Letter, 35:39, 1993), has been approved by the US Food and Drug Administration for use in locally…

Med Lett Drugs Ther. 1996 Sep 27; 38(984):87-8
Docetaxel ( Taxotere - Rh ne-Poulenc Rorer), a semisynthetic taxoid similar to paclitaxel ( Taxol - Medical Letter, 35:39, 1993), has been approved by the US Food and Drug Administration for use in locally advanced or metastatic breast cancer that has progressed or relapsed during treatment that included an anthracycline such as doxorubicin ( Adriamycin , and others).
Issue 978 · July 5, 1996
Anastrozole for Metastatic Breast Cancer

Anastrozole ( Arimidex - Zeneca), a selective nonsteroidal aromatase inhibitor, has been approved by the US Food and Drug Administration (FDA) for treatment of postmenopausal women with advanced breast cancer…

Med Lett Drugs Ther. 1996 Jul 5; 38(978):61-2
Anastrozole ( Arimidex - Zeneca), a selective nonsteroidal aromatase inhibitor, has been approved by the US Food and Drug Administration (FDA) for treatment of postmenopausal women with advanced breast cancer that has progressed during treatment with tamoxifen ( Nolvadex , and others).
Issue 843 · May 3, 1991
Autologous Bone marrow Transplantation For Advanced Breast Cancer

The prognosis in breast cancer is generally poor for women with unresectable, locally advanced disease (inflammatory cancer or more than 10 positive lymph nodes) and for those with metastases. Autologous bone…

Med Lett Drugs Ther. 1991 May 3; 33(843):39-40
The prognosis in breast cancer is generally poor for women with unresectable, locally advanced disease (inflammatory cancer or more than 10 positive lymph nodes) and for those with metastases. Autologous bone marrow transplantation - removing bone marrow from multiple sites under general anesthesia, giving high-dose chemotherapy with or without total body radiation, and reinfusing the bone marrow intravenously - is being tried in some of these patients.
Issue 818 · May 18, 1990
Adjuvant Chemotherapy of Early Breast Cancer

The most important prognostic variable in early breast cancer is axillary lymph node involvement. Based on past experience, after 10 years about 70% of node-negative patients will be alive and apparently free…

Med Lett Drugs Ther. 1990 May 18; 32(818):49-50
The most important prognostic variable in early breast cancer is axillary lymph node involvement. Based on past experience, after 10 years about 70% of node-negative patients will be alive and apparently free of disease; about 30% will have relapsed or died. Patients with positive nodes may have a 30% to 60% relapse rate, depending on the number of positive nodes and other prognostic factors, such as the presence of estrogen receptors (IC Henderson et al, in VT DeVita, Jr et al, eds, Cancer: Principles and Practice of Oncology, 3rd ed, Philadelphia:Lippincott, 1989, p 1197). Which of these patients should receive adjuvant treatment with cytotoxic drugs and/or endocrine therapy is controversial; a National Cancer Institute (NCI) Consensus Conference on this subject is scheduled for June.